Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATOC + CAPTEM in GEP-NETs
NCT04194125Phase 2Unknown
- Sponsor
- University of Warmia and Mazury
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177-edotreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by University of Warmia and Mazury. Primary endpoint: Progression Free Survival at 3 years. Status: unknown.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04194125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194125.